Personalized medicine in lung cancer: what we need to know. (Q37921595)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

Personalized medicine in lung cancer: what we need to know (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

main subject

personalized medicine

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Tony S K Mok

series ordinal

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

23 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

661-668

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21862980%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Theory of traditional Chinese medicine and therapeutic method of diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Somatic mutations affect key pathways in lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Lung cancer in never smokers--a different disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Screening for epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

The clinicopathological features of anaplastic large cell lymphomas expressing p80NPM/ALK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

EML4-ALK fusion lung cancer: a rare acquired event

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

KRAS mutations in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Detection of mutations in EGFR in circulating lung-cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

31 March 2020

Living with imperfection

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.126

A small step towards personalized medicine for non-small cell lung cancer

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21862980